Press releases
9 January 2023, Zwingenberg

Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site

• Dr. Alexander Pelzer appointed as new Head of Research & Development, BRAIN Biotech Zwingenberg site

• Dr. Martin Langer takes on additional responsibility as Managing Director BioScience Operations, Zwingenberg

Biotechnology and enzyme expert BRAIN Biotech AG today announces the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG’s proprietary CRISPR technology, the Group´s management is now pleased to announce that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics.

Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path.

In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.

Adriaan Moelker, CEO of BRAIN Group, says: “I am very happy to promote Alexander to this important position. The fact that we were able to find an optimal successor for Michael Krohn within our company testifies to the development capabilities of our own professionals. Alexander comes with an excellent technical background. He also has the necessary experience in discovery, enzyme and strain optimization, fermentation, expression and scale-up to further drive the expansion of our enzymes and microorganisms business. Martin will be a strong leader of the Zwingenberg team and continue to drive the growth of our TMS business. With these appointments, we are taking an important next step in our journey to become a provider of integrated solutions for our customers."

Dr. Martin Langer
© BRAIN Biotech AG

Press Image 2

Dr. Martin Langer assumes responsibility as Managing Director and Executive Vice President BioScience Operations, Zwingenberg


BRAIN Biotech AG (“BRAIN”) is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products – BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success.

BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. Our products and services target at least five of the UN SDGs directly.

Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).


This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Share this page